Suppr超能文献

肝细胞癌患者树突状细胞的直接离体分析。

Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma.

作者信息

Ormandy Lars-A, Farber Anatol, Cantz Tobias, Petrykowska Susanne, Wedemeyer Heiner, Horning Monique, Lehner Frank, Manns Michael-P, Korangy Firouzeh, Greten Tim-F

机构信息

Department of Gastroenterology, Hepatology und Endocrinology, Medizinische Hochschule Hannover, Carl Neuberg Str. 1, 30625 Hannover, Germany.

出版信息

World J Gastroenterol. 2006 May 28;12(20):3275-82. doi: 10.3748/wjg.v12.i20.3275.

Abstract

AIM

To analyze the phenotype and function of dendritic cells (DC) from patients with hepatocellular carcinoma (HCC) in order to understand their role in this disease.

METHODS

Myeloid dendritic cells were enumerated in peripheral blood of HCC patients. CD80, CD83, CD86 and HLA-DR expression on naive and stimulated myeloid dendritic cells from peripheral blood were analyzed. Myeloid dendritic cells were isolated from peripheral blood and their function was tested. Phagocytosis was analyzed using FITC-dextran beads, peptide specific stimulation, the capacity to stimulate allogeneic T cells and secretion of cytokines upon poly dI:dC was tested.

RESULTS

Myeloid dendritic cells were reduced in patients with HCC. No differences in CD80, CD83, CD86 and HLA-DR expression were found on naive and stimulated myeloid dendritic cells from HCC patients and healthy controls. Normal phagocytosis or stimulation of peptide specific T cells was observed in contrast to an impaired allo-stimulatory capacity and a reduced IL-12 secretion.

CONCLUSION

Impaired IL-12 production of mDCs in patients could lead to an impaired stimulatory capacity of naive T cells suggesting that IL-12 directed therapies may enhance tumor specific immune responses in HCC patients.

摘要

目的

分析肝细胞癌(HCC)患者树突状细胞(DC)的表型和功能,以了解其在该疾病中的作用。

方法

对HCC患者外周血中的髓样树突状细胞进行计数。分析外周血中未成熟和经刺激的髓样树突状细胞上CD80、CD83、CD86和HLA-DR的表达。从外周血中分离髓样树突状细胞并检测其功能。使用异硫氰酸荧光素标记的葡聚糖珠分析吞噬作用,测试肽特异性刺激、刺激同种异体T细胞的能力以及聚肌苷酸:聚胞苷酸刺激后细胞因子的分泌。

结果

HCC患者的髓样树突状细胞减少。HCC患者和健康对照者未成熟和经刺激的髓样树突状细胞上CD80、CD83、CD86和HLA-DR的表达没有差异。观察到正常的吞噬作用或肽特异性T细胞的刺激,而异种异体刺激能力受损且白细胞介素-12分泌减少。

结论

患者髓样树突状细胞白细胞介素-12产生受损可能导致未成熟T细胞刺激能力受损,提示白细胞介素-12导向疗法可能增强HCC患者的肿瘤特异性免疫反应。

相似文献

1
Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma.
World J Gastroenterol. 2006 May 28;12(20):3275-82. doi: 10.3748/wjg.v12.i20.3275.
5
The expression and function of immunoglobulin-like transcript 4 in dendritic cells from patients with hepatocellular carcinoma.
Hum Immunol. 2020 Dec;81(12):714-725. doi: 10.1016/j.humimm.2020.10.003. Epub 2020 Oct 22.
6
Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function.
Scand J Gastroenterol. 2011 Feb;46(2):156-64. doi: 10.3109/00365521.2010.516450. Epub 2010 Sep 7.
7
Immunosuppressive effect of renal cell carcinoma on phenotype and function of dendritic cells.
Int Urol Nephrol. 2014 May;46(5):915-20. doi: 10.1007/s11255-013-0595-8. Epub 2013 Nov 8.
8
The Expression of ILT4 in Myeloid Dendritic Cells in Patients with Hepatocellular Carcinoma.
Immunol Invest. 2019 Oct;48(7):704-718. doi: 10.1080/08820139.2019.1571507. Epub 2019 May 2.

引用本文的文献

1
Inflammation in MASLD progression and cancer.
JHEP Rep. 2025 Apr 2;7(8):101414. doi: 10.1016/j.jhepr.2025.101414. eCollection 2025 Aug.
3
Targeting hypoxia signaling pathways in angiogenesis.
Front Physiol. 2024 Apr 25;15:1408750. doi: 10.3389/fphys.2024.1408750. eCollection 2024.
4
Development of Cell Technologies Based on Dendritic Cells for Immunotherapy of Oncological Diseases.
Biomedicines. 2024 Mar 21;12(3):699. doi: 10.3390/biomedicines12030699.
5
Tumor Immune Microenvironment as a New Therapeutic Target for Hepatocellular Carcinoma Development.
Dev Reprod. 2023 Dec;27(4):167-174. doi: 10.12717/DR.2023.27.4.167. Epub 2023 Dec 31.
7
New Therapeutics for HCC: Does Tumor Immune Microenvironment Matter?
Int J Mol Sci. 2022 Dec 27;24(1):437. doi: 10.3390/ijms24010437.
8
Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows.
World J Gastrointest Oncol. 2022 Sep 15;14(9):1622-1636. doi: 10.4251/wjgo.v14.i9.1622.
9
The future is now: beyond first line systemic therapy in hepatocellular carcinoma.
Transl Cancer Res. 2019 Apr;8(Suppl 3):S261-S274. doi: 10.21037/tcr.2018.11.23.
10
Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges.
Front Cell Dev Biol. 2021 Nov 12;9:775462. doi: 10.3389/fcell.2021.775462. eCollection 2021.

本文引用的文献

1
[Treatment of hepatocellular carcinoma].
Z Gastroenterol. 2006 Jan;44(1):43-9. doi: 10.1055/s-2005-858932.
2
Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients.
Br J Cancer. 2005 May 23;92(10):1862-8. doi: 10.1038/sj.bjc.6602590.
3
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.
Cancer Res. 2005 Mar 15;65(6):2457-64. doi: 10.1158/0008-5472.CAN-04-3232.
5
6
Mechanisms and functional significance of tumour-induced dendritic-cell defects.
Nat Rev Immunol. 2004 Dec;4(12):941-52. doi: 10.1038/nri1498.
8
Immunotherapeutic strategies for hepatocellular carcinoma.
Gastroenterology. 2004 Nov;127(5 Suppl 1):S232-41. doi: 10.1053/j.gastro.2004.09.038.
9
Toll-like receptor control of the adaptive immune responses.
Nat Immunol. 2004 Oct;5(10):987-95. doi: 10.1038/ni1112.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验